Recent studies indicate cell death is the hallmark of cardiac pathology in myocardial infarction and diabetes. The AMP-activated protein kinase (AMPK) signalling pathway is considered a putative salvaging phenomenon, plays a decisive role in almost all cellular, metabolic, and survival functions, and therefore entails precise regulation of its activity. AMPK regulates various programmed cell death depending on the stimuli and context, including autophagy, apoptosis, necroptosis, and ferroptosis. There is substantial evidence suggesting that AMPK is down-regulated in cardiac tissues of animals and humans with type 2 diabetes or metabolic syndrome compared to non-diabetic control and that stimulation of AMPK (physiological or pharmacological) can ameliorate diabetes-associated cardiovascular complications, such as myocardial ischemia-reperfusion injury. Furthermore, AMPK is an exciting therapeutic target for developing novel drug candidates to treat cell death in diabetes-associated myocardial ischemia-reperfusion injury. Therefore, in this review, we summarized how AMPK regulates autophagic, apoptotic, necroptotic, and ferroptosis pathways in the context of myocardial ischemia-reperfusion injury in the presence and absence of diabetes.

1. Introduction

AMP-activated protein kinase (AMPK) is a serine/threonine kinase that responds to perturbed energy status. AMPK is activated when energy levels are low and acts as an energy sensor [1]. Once AMPK is activated, it phosphorylates several downstream substrates that catalyze energy metabolism and cell death mechanisms. For instance, AMPK activation inhibited endothelial cell apoptosis by enhancing BCL2 gene expression [2], a regulator of cell death.

Since cell death is a prominent feature of several pathological diseases, including cardiovascular disease [3] and diabetes mellitus [4], restricting cell demise could be beneficial in alleviating human diseases. Programmed cell death is described as the regulated form of death executed by highly organized intracellular cascade pathways. Three types of programmed cell death have been identified based on morphological criteria: apoptosis, autophagy, necroptosis, and ferroptosis. Human cells develop several protective strategies to suppress cell death, and AMPK activation is regarded as one of the essential salvaging mechanisms against cell death.

In this review, we summarized the role of AMPK in autophagy, apoptosis, necroptosis, and ferroptosis in the...
context of myocardial ischemia-reperfusion injury (MIRI) in the presence and absence of diabetes.

2. AMPK Structure and Regulation

AMPK is a hetero-trimeric enzyme, enclosing catalytic α and regulatory β, γ subunits [5]. AMPK is extensively distributed, and two α isoforms (α1, α2), two β isoforms (β1, β2), and three γ isoforms (γ1, γ2, γ3) of AMPK have been recognized to date [6, 7]. Mostly, the α2 isoform is essential for cardiac AMPK function under basal and stress situations [8]. The α2 isoform is the most predominant (contributing 70-80% of total AMPK activity) within the heart [9]. The β subunit contains a glycogen-binding domain and acts as a bridge between α and γ subunits [10]. The γ subunit contains four tandem C-terminal cystathionine beta-synthetase domains (CBS), which bind AMP and are critical for AMPK regulation [11].

2.1. Allosteric Activation of AMPK by AMP. AMPK has been considered nature’s energy sensor or fuel gauge [12], as its activity is primarily determined by intracellular AMP and ADP levels resulting in a decrease in ATP levels. The binding of AMP or ADP to the AMPKα subunit increases the phosphorylation of Thr172 by upstream kinases and inhibits dephosphorylation by protein phosphatase [13–15]. The binding of AMP or ADP to the γ regulatory subunit of AMPK triggers a conformational change in the AMPK complex that promotes phosphorylation of Thr172 in the AMPKα subunit [14, 16, 17]. However, the binding of AMP, but not ADP, allosterically activated AMPK and amplified the protein phosphorylation up to tenfold [13–15].

Four cystathionine-β-synthase domain repeats present within the AMPKγ subunit have an essential role in the allosteric activation of AMPK in response to cellular adenosine nucleotides (AMP, ADP, or ATP) [18]. These CBS domains are numbered as Sites 1–4 based on the number of conserved aspartate residues involved in ligand binding [18–20]. Site 2 (or CBS2) is always empty and does not bind nucleotides [21], while Site 4 (CBS4) tightly bind AMP molecules under physiological conditions [18]. The other two sites (CBS1 and CBS3) represent the regulatory sites that bind adenine nucleotides (AMP, ADP, or ATP) [18]. It appears that AMP binding to CBS1 causes allosteric activation of AMPK, whereas binding of AMP or ADP to CBS 3 modulates the phosphorylation state of Thr172 [14].

2.2. Regulation of AMPK Activity by Upstream Kinases. Physiological AMPK activation largely depends on the phosphorylation of the crucial Thr172 site within the activation loop of the AMPKα subunit. The phosphorylation status of Thr172 is determined by the balance of action of upstream kinases and protein phosphatases. Two upstream kinases, liver kinase B1 (LKB1) [22] and Ca2+/calmodulin-dependent protein kinase β (CaMKKβ) [23], have been reported to phosphorylate Thr172 of AMPKα.

Liver kinase B1 (LKB1) is a serine/threonine kinase first recognized as a tumor suppressor mutated in the Peutz-Jeghers syndrome, an inherited form of susceptibility to cancer [24], LKB1 functions as a hetero-trimeric complex with two additional proteins to function, kinase-dead STE20-related kinase (STRAD) and Mouse protein 25 (MO25) [22]. In normal physiological conditions, the LKB1/STRAD/MO25 complex is a constitutively active kinase [25], while in their absence (lack of STRAD and MO25 binding to LKB1), the LKB1 is a weakly active kinase [22]. Studies in the LKB1 deficient mouse have shown that LKB1 is the primary upstream AMPK kinase in most mammalian tissues, including the heart [26], muscle, and liver [27–29]. In the heart, phosphorylation of AMPKα2 is entirely dependent on LKB1 during ischemia [14]. In skeletal muscle, LKB1 deficiency severely impaired AMPKα phosphorylation after ex-vivo contraction or stimulation of AMPK with the pharmacological AMP-mimetic AICAR (aminomimidazole-4-carboxamide-1-β-D-ribofuranoside) [27, 29]. In the liver, LKB1 deletion abolished the effects of metformin on AMPK stimulation and glucose synthesis [28].

Ca2+/calmodulin-dependent protein kinase β (CaMKKβ), another potential upstream kinase, can activate AMPK in response to calcium flux independently of AMP/ADP/AMP levels. CaMKKβ is the major isoform that phosphorylates AMPK at Thr172 in the brain and other non-cardiac cells [30]. CaMKKβ has been shown to stimulate AMPK following hypoxia [31, 32] and amino acid starvation [33]. However, CaMKKβ can maintain AMPK activity that is still sensitive to changes in the nucleotide (ATP-to-AMP) ratio in LKB1-deficient cells [34]. In contrast, CaMKKα may be the dominant upstream kinase isoform in skeletal muscle [35].

Transforming growth factor-β-activated protein kinase-1 (TAK1), another upstream kinase of AMPK, has been studied in cultured cardiomyocytes. TAK1 phosphorylates Snf1, the yeast homolog of the mammalian AMPK α-subunit [36]. Although TAK1 is activated during cardiac ischemia, it appears to regulate LKB1 kinase activity rather than phosphorylating AMPK [37].

Kinas, such as protein kinase A and Akt, responsible for phosphorylation at serine residues, also modulate AMPK activation. Protein kinase A phosphorylates Ser173 on the AMPKα subunit and blunts the Thr172 phosphorylation by upstream AMPK kinases [38]. Akt and protein kinase A phosphorylate Ser485 in α1 and the corresponding Ser491 in α2 subunits, inhibiting Thr172 phosphorylation [39]. It has been demonstrated that constitutively active Akt blunts the AMPK activation in the heart by phosphorylation of Ser485 or Ser491 residues [40].

Protein phosphatases PP2A and PP2C also regulate AMPK activity by dephosphorylating Thr172 [16]. The binding of AMP to the γ subunit of AMPK blunts the action of PP2C to dephosphorylate Thr172 in vitro [13]. Regulation of AMPK activity also depends on the alterations in protein phosphatase expression in the heart; for example, enhanced PP2C expression reduced AMPK activity in the rodent cardiac lipotoxicity model (Zuker diabetic fatty rats) [41]. Elevated serum fatty acids decrease AMPK phosphorylation by stimulating PP2A activity in endothelial cells [42]. However, it is still unclear which of the specific phosphatases are
physiologically responsible for maintaining the low basal activity of AMPK by dephosphorylating Thr172 in the normal heart.

3. AMPK Physiological Functions

AMPK acts as a “cellular fuel gauge” in cardiac cells to preserve energy (ATP) during times of stress, such as myocardial ischemia [6]. AMPK activation preserves energy by inhibiting energy-consuming metabolic pathways and increasing energy-producing metabolic processes via phosphorylation of downstream targets. AMPK activation can lead to phosphorylation at serine/threonine residues [43] of multiple substrates involved in various metabolic functions such as lipid metabolism [e.g., acetyl-CoA carboxylase (ACC); 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR)], glucose metabolism [e.g., 6-phosphofructo-2-kinase (PFK2); glycogen synthase], and protein metabolism are summarized in Table 1.

Table 1: Metabolic functions of AMPK.

| Direct/indirect activation via | Downstream target | Stimulation/inhibition | Metabolic effect | Reference |
|-------------------------------|-------------------|------------------------|-----------------|-----------|
| Indirect activation via TBC1 domain family member 1 | Glucose transporter type (GLUT) 4 GLUT1 | Stimulation | Glucose uptake | [44, 45] |
| Indirect activation via p38 mitogen-activated protein kinase | PFK2 | Stimulation | Glycolysis | [47] |
| Direct | Glycogen synthase | Stimulation | Glycogen synthesis | [48] |
| Direct | Phosphoenolpyruvate carboxykinase | Inhibition | Gluconeogenesis | [49] |
| Indirect activation via cAMP response element-binding-(CREB-) regulated transcription coactivator 2 | Glucose-6-phosphatase | Inhibition | Gluconeogenesis | [50] |
| Indirect activation via phosphorylates histone deacetylase | Glucose-6-phosphatase | Inhibition | Gluconeogenesis | [50] |
| Direct | Translocation of CD36 | Stimulation | Fatty acid uptake | [51] |
| Direct | ACC2 | Stimulation | Fatty acid oxidation | [52] |
| Direct | ACC1 | Inhibition | Fatty acid synthesis | [53] |
| Direct | Sterol regulatory element-binding protein 1C | Inhibition | Lipogenesis | [54] |
| Direct | Glycerol phosphate acyl transferase | Inhibition | Triglyceride synthesis | [55] |
| Direct | HMGR | Inhibition | Cholesterol synthesis | [56] |
| Indirect activation via phosphorylates transcription initiation factor IA | RNA polymerase I | Inhibition | Ribosomal RNA synthesis | [57] |
| Direct | Mammalian target of rapamycin (mTOR) | Inhibition | Protein synthesis | [43] |
| Indirect activation via activate tuberous sclerosis (TSC) 2 | mTOR | Inhibition | Protein synthesis | [58] |
| Direct | Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α) | Stimulation | Mitochondrial biogenesis | [59] |
| Indirect activation via Sirtuin1 | PGC1α | Stimulation | Mitochondrial biogenesis | [60] |

4. AMPK Role in Cell Death Modalities in Myocardial Ischemia-Reperfusion Injury

4.1. Autophagy. Autophagy is an essential catabolic process to degrade and recycle long-lived biosynthetic substrates such as ATP with the help of autophagy machinery, which consists of double-membrane autophagosomes and lysosomes [61]. Baseline autophagy is deemed indispensable in terminally differentiated cells like cardiomyocytes than in regenerative cells because dysfunctional organelles and long-lived proteins are degraded to maintain their global structure and function. For example, deletion of the autophagy-related gene (ATG) 5 in the heart produces contractile dysfunction and cardiac hypertrophy [62]. This study emphasizes the vital homeostatic role of autophagic clearance of cytosolic proteins to survive heart cells. Furthermore, cardiac function is decreased in mice deficient in lysosome-associated membrane protein-2 (LAMP-2), a protein essential for a terminal event of the autophagic cascade, i.e., autophagosome-lysosome fusion, mimicking the...
clinical manifestations of Danon disease (autophagic vacuolar myopathy) resulting due to the mutation in LAMP-2 [63, 64].

A central negative controller of autophagy is the mammalian target of rapamycin (mTOR) complex (mTORC)1 formed by mTOR, RAPTOR, and mLST8, and the suppression of mTORC1 initiates autophagy [65, 66]. AMPK has been considered a negative regulator of mTORC1 and a positive regulator of autophagy, acting indirectly by phosphorylating tuberous sclerosis complex 1 and 2 (TSC1/2) [58] or directly by phosphorylating RAPTOR [67]. The exact mechanism by which AMPK stimulates autophagy is still unknown; however, existing literature proposes different possibilities for its activation: one possibility is the dissociation of the BECLIN-1–BCL2 complex via c-jun N-terminal protein kinase (JNK)1 [68]. The dissociated BECLIN-1 interacts with vacuolar protein sorting (VPS) 34 to commence phagophore development. Secondly, AMPK activates the expression of autophagy-related genes such as microtubule-associated proteins 1A/1B light chain 3A, GABA(A) receptor-associated protein-like 1, and ATG12 through forkhead box O (FOXO)1 and FOXO3 activation [69, 70]. The third possibility is that AMPK phosphorylates and activates unc-51, like autophagy activating kinase (ULK)1 [71, 72]. Furthermore, putative upstream kinases of AMPK, such as LKB1 [73], and CaMKK-β [74], induce autophagy in different tissues by activating the AMPK-mTOR pathway. However, conflicting results have been observed with pharmacological agents, such as 5-amino-4-imidazole carboxamide riboside (AICAR), and activation of AMPK inhibits autophagy [75] could be related to its nonspecific effects, probably via protein kinase B activation of mTORC1 [76]. The results observed with compound C (AMPK inhibitor) [77] are parallel with observations of a dominant-negative form of AMPK inhibition of fasting elicited autophagy. Thus, AMPK can be a crucial mediator in integrating energy-sensing events with downstream autophagy stimulation (Figure 1).

4.1.1. AMPK and Autophagy in MIRI. Cardiac autophagy was first observed in 1976 by Sybers et al. They observed the presence of autophagosomes and suggested its role in the repair of sub-lethal injury in fetal mouse hearts [78]. Later on, cardiac autophagy research increased tremendously only after 2000 [64, 79]. Enhanced autophagy was observed in human [80], pig [81, 82], mice [83], and rat [84] hearts and neonatal and adult cardiomyocytes [85] subjected to ischemic and ischemia/reperfusion (I/R) conditions. Robust autophagy has been associated with cardiac disorders like chronic ischemia, IR injury, and enhanced afterload [86]. These studies suggest that autophagy was activated during ischemia and increased during and after reperfusion. The critical role of AMPK in the stimulation of autophagy is evident in the ischemic condition where a rapid decline in ATP:ADP (potent inducer of AMPK) occurs [87]. For instance, glucose deficit-augmented and ischemia-provoked autophagy are suppressed in dominant-negative AMPK overexpressed cardiomyocytes and mice, respectively [83]. Furthermore, in support of the protective function of AMPK during ischemia, Takagi et al. reported that chronic ischemia produced a large infarct size accompanied by cardiac dysfunction in the dominant-negative AMPK mice [88]. However, ATP depletion may not be the primary stimulus for autophagy induction during reperfusion, where ATP availability is abundant. Other mechanisms like reactive oxygen species (ROS) [89], endoplasmic reticulum stress [90], and calpain [91] are proposed to be the primary regulators of autophagy during energy replenished reperfusion state. AMPK promotes ischemic post-conditioning-induced cell survival in the ischemic heart via endothelial nitric oxide synthase- (eNOS-) mediated cardiomyocyte autophagy [92].

**Figure 1: Role of AMPK in autophagy regulation**
In the heart, depending on the milieu and magnitude of induction, autophagy can bestow both adaptive and maladaptive actions [93]. For instance, autophagy is generally protective during ischemia, but contrary to this, autophagy during reperfusion is detrimental, thus exhibiting phase-dependent contrasting biological functions [83]. The molecular mechanism operating autophagy induction differs in both circumstances, leading to unexpected distinct roles (Figure 1). Ischemia activates autophagy induction through AMPK-mediated inhibition of the mTOR pathway, whereas reperfusion activates autophagy via an AMPK-mTOR-independent manner, mainly through BECLIN-1 [83, 88]. In addition, it has been speculated that supra-physiological levels of autophagy by dramatic up-regulation of BECLIN-1, BNIP3, and other lysosomal enzymes [94, 95], the distorted balance between BCL2 and BECLIN-1 [95], down-regulation of BCL2 [96], and concomitant stimulation of apoptotic pathways via calpain degradation of ATG5 [97] are some of the causative factors for the detrimental facet of autophagy.

4.1.2. AMPK and Autophagy in MIRI in the Presence of Diabetes. In type 2 diabetes (characterized by insulin resistance), cardiac autophagy is upregulated and is linked to the down-regulation of phosphoinositide 3-kinase (PI3K)-Akt (insulin pathway), another negative regulator of autophagy [98], and down-regulation of this pathway is the key attribute of cardiac insulin resistance [99]. It has been observed that up-regulation of cardiac autophagy is associated with detrimental anomalies such as elevated ROS and loss of cardiomyocyte viability in 12 weeks (3 months) fructose-fed mice [98], which is contradictory to normal ischemia-induced autophagy where decreased PI3K pathway coincides with protective autophagy [100]. Chronic dysregulation of lipid metabolism, defective insulin signalling, and other metabolic alterations could influence the cardiac ability of stress response in a distinct way from acute vs chronic ischemia damage. One possibility is that diabetes may impair autophagic flux; however, it further warrants investigation.

In type 1 diabetes (characterized by insulin deficiency), cardiac autophagy is down-regulated and is related to the down-regulation of AMPK [101, 102]. Decreased autophagy was observed in hearts of streptozotocin- (STZ-) induced diabetic rodents (6 months) and OVE26 mouse (well-characterized genetic model of type 1 diabetes) [101], in contrast to findings observed in type 2 diabetic models where autophagy is activated. Decreased autophagy is a compensatory mechanism that helps prevent cardiac damage in type 1 diabetes [103]. The possible explanation for such disparate observations in these two diabetic situations may be linked to variability in the insulin signalling pathways, differential duration of disease progression, and severity of extracellular insulinemic/glycemic exposure to cardiac tissue.

Firstly, the dual role of AMPK activation and PI3K-Akt down-regulation may congregate and deliver a potent stimulus for mTOR suppression in type 2 diabetic hearts, whereas PI3K-Akt suppression is less evident or perhaps lacking in type 1 diabetic hearts (Figure 1). In addition, the role of AMPK in type 1 diabetic conditions is perplexing. Down-regulation of myocardial AMPK is repeatedly reported in various models, although unaltered and increased AMPK activity is also evident [101, 104–106]. Furthermore, there may be a possibility for the differential role of mTOR in autophagy regulation in both these conditions, which was not measured in the STZ-treated and fructose-fed models. Secondly, the duration of disease progression for both type 1 and type 2 models are different, i.e., six months and three months, respectively. Finally, hyperglycemia may also influence autophagy signal transduction through glycosylation and glycation, which would be more prominent in type 2 fructose-fed models since fructose is a potent glycosylation agent. Thus, a comprehensive scrutiny of autophagy activation during disease progression and cardiac insulin resistance associated with plasma glucose and insulin levels could yield precise mechanistic relations.

AMPK stimulates autophagy by inhibiting mTOR directly or indirectly (via TSC1/2) and activating ULK1 and FOXO1/3. In type 2 diabetic conditions, activated AMPK and decreased PI3K-Akt pathway collectively operate and stimulate autophagy. However, in type 1 diabetes, reduced AMPK activation results in decreased autophagy and probably acted via inhibiting JNK1 facilitated Beclin-1-Bcl2 complex formation. Ischemia (low ATP levels) triggers AMPK-mTOR mediated autophagy, whereas reperfusion follows AMPK independent pathway, i.e., the Beclin1 pathway, to stimulate autophagy.

4.2. Apoptosis. Apoptosis is an energy-dependent, highly programmed cell death with distinct phenotypic features, like cell shrinkage, fragmented nucleus, condensed chromatin, and plasma membrane blebbing with apoptotic body formation [107]. There are two types of apoptotic cell death, extrinsic apoptosis and intrinsic apoptosis; both can lead to activation of the caspase cascade [108, 109].

Extrinsic apoptosis can be activated by a variety of death ligands such as Fas ligand [110], tumor necrosis factor (TNF)-α [111], TNF-related and apoptosis-inducing ligand (TRAIL) [112] upon binding to their death receptor, e.g., Fas receptor, TNF receptor (TNFR), and DR4 respectively, thereby eventually leading to generation of death-inducing signalling complex (DISC). The DISC consists of several adaptor proteins like TNFRI associated via death domain (TRADD) [113] and Fas associated via death domain (FADD) [114], receptor-interacting protein (RIP) 1, and caspase-8. Activation of caspase-8 subsequently stimulates caspase-3 and -7 and promotes the breakdown of critical proteins in the cell [115].

Unlike extrinsic apoptosis, which relies on ligand-receptor interaction at the plasma membrane surface, the intrinsic apoptotic pathway can be activated by a wide range of stimuli like oxidative stress, hypoxia, DNA damage, and nutrient stress. The intricate balance between proapoptotic (BAX, BAK, BID) and anti-apoptotic (BCL-2, BCL-xL) proteins of the BCL-2 family is decisive for the induction of this pathway [116]. Upon activation, translocation of Bax to mitochondria triggers the release of cytochrome c and other apoptogens like the second mitochondria-derived activator

Oxidative Medicine and Cellular Longevity
of caspase (SMAC), also known as DIABLO and apoptosis-inducing factor (AIF), by facilitating permeabilization of outer mitochondrial membrane [117, 118]. In the cytosol, the secreted cytochrome c forms an apoptosome complex by interacting with apoptotic protease activating factor-1 (APAF-1), activating caspase-9, and enabling further caspase-mediated apoptosis [119].

4.2.1. AMPK and Apoptosis in MIRI. Much of the cell death in myocardial ischemia and reperfusion is accomplished through apoptosis [120]. Permanent coronary occlusion (ischemia) triggered apoptosis [120], whereas reperfusion restores ATP essential for the execution of apoptosis and appears to boost apoptosis [121, 122]. Diminished infarct size is evident in Fas deficient lpr mice [123], transgenic mice overexpressing BCL-2 [124], and BAX-deficient mice [125] after I/R. Furthermore, deletion of both TNFR1 and TNFR2 resulted in significant infarct size following permanent coronary ligation [126]. This evidence suggests that extrinsic and intrinsic apoptotic pathways play a crucial role in determining infarct size during I/R and MI.

AMPK has been shown to exhibit both proapoptotic and anti-apoptotic actions in cardiomyocytes; however, overwhelming cardiac studies suggested that AMPK stimulation is anti-apoptotic. Capano and Crompton demonstrated that the proapoptotic effects of AMPK are mediated by mitochondrial translocation of BAX [127]. In contrast to this, Kewalramani et al. have shown that stimulation of AMPK strikingly prevented TNF-α-induced cardiomyocyte apoptosis and is mediated by promoting BAD phosphorylation (proapoptotic protein) and eventually inhibiting mitochondrial apoptotic signalling events like cytochrome c release and caspase 3 activations by restricting its association with BCL-XL (anti-apoptotic protein) [128]. Similarly, AMPK stimulation is indispensable in protecting against oxidative stress-induced apoptosis in H9C2 rat cardiomyocytes [129, 130] and palmitate-induced apoptosis in neonatal cardiomyocytes [131]. Russell et al. showed thatAMPK activation is beneficial in decreasing apoptosis in the ischemic heart of transgenic mice expressing kinase-dead mutants of AMPKα2 primarily by improving metabolic effects like glucose uptake and glycolytic flux [8]. Besides, Shibata et al. demonstrated that the anti-apoptotic function of adiponectin against myocardial ischemia/reperfusion is mediated by AMPK activation [132]. A recent study also revealed that AMPK is required for the cardioprotective effect of exogenous NADPH against myocardial I/R-induced cardiac apoptosis through activating the mTOR pathway [133]. Thus, AMPK is crucial in limiting cardiac apoptosis associated with I/R (Figure 2).

4.2.2. AMPK and Apoptosis in MIRI in the Presence of Diabetes. Diabetes makes the cardiac tissue more vulnerable to I/R injury [134]. Apoptosis occurs in both type 1 and type 2 diabetic hearts, not only during the early stage of diabetes but also extends to a later stage of diabetes [135–137]. Exposure of H9C2 [135] and adult cardiomyocytes [138, 139] to overly glucose induced a significant rise in apoptotic cell death, indicating a direct relationship between hyperglycemia and myocardial apoptotic cell death. Other factors like hyperlipidemia [140], ROS, and reactive nitrogen species formation [141] could also influence diabetes-induced myocardial cell death.

Diabetes triggers apoptotic cell death and diminishes autophagy, thereby regulating the interplay between cardiac apoptosis and autophagy. AMPK plays a crucial role in the switch between these two cell deaths in diabetic conditions. He et al. reported that diminished AMPK activity is linked
to diabetes-triggered apoptosis and concomitantly reduced autophagy. Diabetes impairs AMPK activation of MAPK8/ JNK1/BCL2 signalling and subsequent BECN1-BCL2 disso-

ciation, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of dia-

betic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phytonutrient) prevented diabetes impairs AMPK activation of MAPK8/JNK1/BCL2 signalling and subsequent BECN1-BCL2 disassociated, promoting apoptosis by suppressing autophagy [68, 142] (Figure 2). In addition, long-term treatment with metformin (AMPK activator) reduced apoptosis, increased autophagy, and preserved cardiac contractility in STZ-induced diabetic mice, suggesting AMPK’s role in the switch between apoptosis and autophagy in the development of diabetic cardiomyopathy [68, 142]; however, it remains to be elucidated. Additionally, exenatide (an anti-diabetic drug) and pterostilbene (a polyphenolic phyto
fibroblasts to N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), H2O2, and TNFα-induced necroptosis; activated AMPKα suppressed necroptosis [175]. Mechanistically, AMPKα is physically associated with keap1 and PGAM5, promoting Keap1-mediated degradation of PGAM5 upon necroptosis induction. More importantly, AMPK activator metformin salvaged the myocardium by attenuating myocardial IR-induced necroptosis and increased cardiac function in Langendorff-perfused hearts through down-regulating PGAM5 expression [175] (Figure 3). These findings suggest that AMPK may be a promising therapeutic target for inhibiting MIRI-induced necroptotic cell death in ischemic heart disease. However, until now, it is uncertain how AMPK regulates cardiac necroptosis and its relation with RIP1, RIP3, and MLKL. Whether it holds RIP1-dependent or independent necroptosis in the context of MIRI and diabetes? What downstream events might be linked to AMPK stimulation in the execution of necroptosis? Further research on those questions will enhance our understanding of AMPK’s role in necroptosis.

TNF-α binding to its corresponding receptor TNFR1 stimulates complex II formation, consisting of TRAF2, FADD, TRADD, RIP1, and RIP3. RIP1 phosphorylates RIP3 and executes necroptosis through its downstream substrate MLKL. MLKL mediates PGAM5-dependent necroptosis. AMPK stimulation by metformin prevents necroptosis via ubiquitination of PGAM5 through the stabilization of Keap1.

4.4. Ferroptosis. Ferroptosis is classified as an iron- (Fe2+) and lipotoxicity-reliant form of regulated cell death characterized by accumulation of reactive oxygen species (ROS) and lipid hydroperoxides derived from iron metabolism [176, 177]. The morphological characteristics of ferroptosis are unique and distinct from apoptosis, necrosis, and autophagy and feature a ruptured mitochondrial outer membrane and shrunken mitochondria with loss of cristae [176, 177]. Initiation of ferroptosis is triggered by the inactivation of the lipid peroxide repair network including the glutathione-glutathione peroxidase 4 (GPx4) axis, namely, restraining the activity of cysteine-glutamate antiporter (system xc’), which decreases the input of cysteine into the cells, resulting in the glutathione (GSH) depletion that leads to accumulation of lipid hydroperoxides and subsequent cell death [176–179]. An ex-vivo study showed that the iron chelator deferoxamine decreased infarct size following global IRI in mouse hearts [180]. Notably, ferrostatin-1 (ferroptosis inhibitor) inhibited cardiac death both in heart transplantation and the traditional coronary artery ligation MIRI models in vivo [181]. Besides, liproxstatin-1, a ferroptosis inhibitor, increased Gpx4 protein level and decreased mitochondrial ROS production in the IR model [182]. From a clinical perspective, these results suggesting that inhibition of ferroptosis may be a useful target in the treatment of cardiomyopathy by preventing iron overload-induced heart failure.

4.4.1. AMPK and Ferroptosis in MIRI. A strong rationale for investigating ferroptotic cell death in the heart is that iron accumulation was observed in the peri-infarct zones of cardiac tissue in reperfused MI patients [183]. Recent studies also support that ferroptosis plays a crucial role in developing MIRI [180, 184–186]. In mouse models, IR has resulted in iron accumulation in cardiomyocytes around the myocardial scars [184]. This study also validated the role of the mammalian target of rapamycin (mTOR) in iron-induced ferroptosis as demonstrated that overexpression of mTOR reduced ROS generation and cardiac cell death induced by Fe2+ and ferroptosis agonists such as the system xc’ inhibitor (erastin) or the GPx4 inhibitor (Ras synthetic lethal 3). Conversely, knockout of mTOR enhanced ferroptosis by these stimuli, and the mechanism may involve mTOR modulation of ROS generation [184] (Figure 4). It has been speculated
that mTOR affects ferroptosis by impacting iron handling via increasing the ferroportin expression, targeting multiple iron transport proteins, and regulating transferrin receptor 1 [187, 188].

Additionally, Nrf2 has been associated with ferroptotic cell death during MI. Nrf2 is the transcription factor that mediates antioxidant responses and inhibits ferroptosis in several cell types by rescuing them from lethal oxidative stress [189, 190]. It has been proposed that Nrf2 upregulates heme oxygenase (HO-1) activity in the early and middle stages of MI, leading to the iron accumulation that contributes to ferroptosis in cardiac cells. Mechanistically, activation of HO-1 catalyzes heme degradation in the heart and facilitates the release of free iron, and triggers lipid peroxidation and ferroptosis, subsequently leading to heart failure. Interestingly, blocking either HO-1 or ferroptosis significantly decreased doxorubicin-induced cardiomyopathy and heart failure, similar to the protective effects of iron chelation with dexrazoxane [186] (Figure 4). These studies concluded that ferroptosis mediates the pathogenesis of IR-induced cardiomyopathy and doxorubicin-induced cardio-toxicity via the Nrf2-HO-1 signalling pathway.

Recent studies revealed that AMPK is involved in ferroptosis. In vivo studies showed that AMPK was downregulated in the heart and kidney challenged with IR injury. Its stimulation by 2DG or AICAR significantly alleviated IR-induced ferroptosis and renal/cardiac damage [149, 191]. Mechanistically, during glucose starvation, AMPK activation phosphorylates acetyl-CoA carboxylase 1 and 2 (ACC1/2), which inhibits de-novo synthesis of fatty acids and subsequent fatty acid oxidation. Decreased levels of polyunsaturated fatty acid also accompanied stimulation of AMPK-containing lipids (PUFA), which may be another reason for ferroptosis inhibition by AMPK (Figure 4). Inactivation of AMPK essentially abolishes the protective effects of energy stress on ferroptosis and reveals an inhibitory role of AMPK in regulating ferroptosis [191]. Therefore, it can be suggested that AMPK activators may be helpful in the treatment of pathological conditions associated with ferroptosis, such as MIRI. In conclusion, although in many cardiovascular diseases, AMPK has already been known as a multifactorial defensive molecule through fatty acid metabolism [192], glucose metabolism [193], oxidative stress [193], mitochondrial biosynthesis [194], autophagy [195], and apoptosis [196], and its underlying mechanisms in ferroptotic cell death remains to be elucidated.

4.4.2. AMPK and Ferroptosis in MIRI in the Presence of Diabetes. High glucose-induced lipid peroxidation plays a critical role in the development of diabetes and cardiovascular complications [197, 198], indicating a broader role of glucose in controlling oxidative damage. In cancer cells, it has been established that high glucose-induced ferroptosis via SLC2A1-mediated glucose uptake, followed by increased glycolysis and pyruvate oxidation, fuels the tricyclic acid cycle and enhances fatty acid synthesis, leading to lipid peroxidation-dependent ferroptosis death [199]. Recent evidence also suggests that ferroptosis plays a vital role in the development of metabolic diseases, for example, diabetes and its complications (e.g., diabetic cardiomyopathy and diabetic MIRI) [200, 201] or, more specifically, inducing or inhibiting ferroptosis significantly impact these diseases [202].

The occurrence of ferroptosis in diabetic rats is accompanied by the endoplasmic reticulum stress and activation of the ATF4-C/EBP homologous protein (CHOP) pathway. Li et al. revealed that blocking ferroptosis decreased ATF4/CHOP-mediated endoplasmic reticulum stress and MIRI-induced cardiac injury in diabetic rats and H9c2 cells [203]. Endoplasmic reticulum stress can be initiated by ROS, which is generated by the interaction between iron...
ions and NADPH oxidase (Nox) during ferroptosis. Under diabetic conditions, oxidative stress associated with programmed cell death was elevated and supposed to reduce AMPK expression, contributing to an increased level of Nox, whose primary role is to generate ROS [149]. Additionally, diabetes amplifies MIRI-induced ferroptosis through activating Nox2-related oxidative stress, while AMPK activation safeguards diabetic rats from myocardial IRI and ferroptosis through inhibition of Nox2 [149].

It has been reported that AMPK is required for SIRT3-induced autophagy. SIRT3 can enhance autophagy by promoting AMPK phosphorylation, inhibiting mTOR activity, and promoting GPx4 levels [204]. Thus, autophagy activation can lead to iron accumulation and lipid peroxidation, which subsequently supports ferroptotic cell death [176, 205]. Significantly, uncontrolled autophagic flux is involved in iron dyshomeostasis in response to ferroptosis [206, 207]. Furthermore, AMPK inhibition partially abolished SIRT3-induced ferroptosis in trophoblasts [208] (Figure 4). Interestingly, Song et al. reported an unexpected finding that AMPK activation promotes ferroptosis, which contradicts its inhibitory role in ferroptosis [209]. The function of AMPK is required for Beclin 1 (BECN1) phosphorylation, which blocks system xc- activity via binding to its core component, SLC7A11 (solute carrier family 7 members 11), and subsequently promotes lipid peroxidation in ferroptosis [209]. Furthermore, SLC7A11-mediated cysteine uptake was not affected substantially by AMPK deletion or its activation by AICAR or 2DG treatment [209] (Figure 4). Therefore, it is possible that AMPK function in the regulation of ferroptosis is context-dependent, which requires further studies.

A recent experiment revealed that myocardial autophagy is disserved in diabetic settings, leading to cardiac damage and cell death, mainly due to ferroptosis triggered by the Nrf2 activation [210]. Interestingly, AMPK activation assists the nuclear translocation of Nrf2 [211, 212]. Using an ex-vivo model of diabetic cardiomyopathy induced by advanced glycation end-products (AGE) in engineered cardiac tissue and type 2 diabetic mice model, it has been demonstrated that AMPKα2 is crucial for the sulfonaphane-associated prevention of cardiomyopathy by inhibiting ferroptosis. The mechanism may involve AMPK/AKT/GSK3β/Nrf2 signaling pathway [213–216] (Figure 4). Therefore, these results suggest that ferroptosis is an essential mechanism in the pathogenesis of diabetic cardiomyopathy, which could be blocked by the activation of Nrf2 in an AMPK-dependent manner. It can be proposed that AMPK represents a mechanistic link between ferroptosis and autophagy. Targeting AMPK may help treat diabetic cardiac complications, such as MIRI.

Under diabetic conditions, high glucose-induced advanced glycation end-products (AGE) inhibit the expression of SLC7A11, which decreases the GSH levels by reducing cysteine uptake by system xc- and increases the free iron levels to induce lipid peroxidation and ferroptosis in the heart. Sulforaphane promotes the Nrf2 nuclear translocation and stimulates the downstream expression of SLC7A11 (solute carrier family 7 members 11) via activation of AMPK, which inhibit cardiac ferroptosis. Nrf2 activation also upregulates heme oxygenase (Hmox1) activity, leading to heme degradation and facilitating the release of free iron accumulation that contributes to lipid peroxidation and ferroptosis in cardiac cells. High glucose-induced mitochondrial dysfunction enhances SIRT3 levels to stimulate autophagy by activating the AMPK-mTOR signalling pathway and eventually leading to ferroptosis. Additionally, BECN1, a positive autophagy regulator, is also involved in ferroptosis by directly inhibiting system xc- activity by bandito to SLC7A11. AMPK-mediated phosphorylation of BECN1 is required for the BECN-1 mediated ferroptosis. Interestingly, glucose starvation or energy stress activates AMPK, which then phosphorylates and inactivates ACC1/2, leading to inhibition of PUFA biosynthesis, lipid peroxidation, and ferroptosis.

5. Future Clinical Perspective

Besides, a comprehensive understanding of cell death processes will be obligatory for developing therapeutic strategies; it is likely to envision harnessing AMPK as a potential therapeutic drug target to modulate cardiac cell death for clinical utility. Two classes of anti-diabetic drugs, metformin and glitazone, are the only currently approved drugs for acute myocardial infarction, which indirectly activates AMPK by raising the AMP/ATP ratio [217, 218]. Because of metformin’s ability to reduce cardiac cell death by AMPK activation, its therapeutic use extends beyond acute coronary syndrome to cardiac transplantation [219]. Acute rosiglitazone therapy may prove beneficial in acute coronary syndrome through AMPK stimulation despite its chronic treatment associated with cardiac mortality [220, 221]. Additionally, AMPK may suppress more than one cell death mechanism; thus, comprehensive knowledge of the role of AMPK in cross-talk mechanisms of cell death is vital to moving ahead. Although AMPK activation results in beneficial functions in the energy-stressed myocardium and cardiovascular system, a particular focus should be given to the harmful regulation of unwarranted fatty acid oxidation during its chronic activation [222]. However, specific vital questions must be answered to understand the translational significance of AMPK activation in cell death mechanisms. For instance, how do various risk factors regulate AMPK activity to alter metabolic and cell death processes? How does AMPK control cross-talk between autophagy, apoptosis, and necroptosis in the context of MIRI? Does AMPK activation confer cardioprotection against ischemic heart disease in clinical conditions? Do AMPK activators show an attractive therapeutic strategy for insulin-resistant type 2 diabetic patients? Thus, further research is necessary to address these issues to understand the clinical significance of AMPK activation in ischemic heart disease.

**Abbreviations**

AMPK: AMP-activated protein kinase

MIRI: Myocardial ischemia-reperfusion injury

CaMKKβ: Calcium/calmodulin-dependent kinase kinase β

TAK1: Transforming growth factor-β-activated protein kinase-1
PP: Protein phosphatase
PFK2: 6-Phosphofructo-2-kinase
ACC: Acetyl-CoA carboxylase
HMGR: 3-Hydroxy-3-methyl-glutaryl-CoA reductase
GLUT: Glucose transporter
CREB: cAMP response element binding
mTOR: Mammalian target of rapamycin
TSC: Tuberous sclerosis
PGC1α: Peroxisome proliferator-activated receptor-γ coactivator 1α
ULK: unc-51-like autophagy activating kinase
FOXO: Forkhead box O
ejNK: c-jun N-terminal protein kinase
PGAM5: Phosphoglycerate mutase-5
mPTP: Mitochondrial permeability transition pore
MLKL: Mixed lineage kinase domain-like
RHIM: RIP homotypic interacting motif
NF-κB: Nuclear factor-κB
LAMP-2: Lysosome-associated membrane protein-2
FOXO: Forkhead box O
JNK: c-jun N-terminal protein kinase
MOMP: Mitochondrial outer membrane
APAF-1: Apoptotic protease activating factor
MOMP: Mitochondrial outer membrane
TRAIL: TNF-related apoptosis-inducing ligand
TRADD: TNFR1 associated via death domain
DISC: Death-inducing signaling complex
TNFα: Tumor necrosis factor-α
p53K: Phosphoinositide 3-kinase
STZ: Streptozotocin
TRAIL: TNF-related apoptosis-inducing ligand
TRADD: TNF receptor-associated death domain
DISC: Death-inducing signalling complex
TRAIL: TNF-related apoptosis-inducing ligand
MTOR: Mammalian target of rapamycin
CREB: cAMP response element binding
GLUT: Glucose transporter
HMGR: 3-Hydroxy-3-methyl-glutaryl-CoA reductase
PP: Protein phosphatase

Authors’ Contributions
All authors participated in drafting and revising the article. All authors read and approved the final manuscript.

Acknowledgments
All figures were created with BioRender.com.

References
[1] D. Carling, “The AMP-activated protein kinase cascade - a unifying system for energy control,” Trends in Biochemical Sciences, vol. 29, no. 1, pp. 18–24, 2004.
[2] C. Liu, B. Liang, Q. Wang, J. Wu, and M. H. Zou, “Activation of AMP-activated Protein Kinase α1 Alleviates Endothelial Cell Apoptosis by Increasing the Expression of Anti-apoptotic Proteins Bcl-2 and Survivin,” The Journal of Biological Chemistry, vol. 285, no. 20, pp. 15346–15355, 2010.
[3] R. S. Whelan, V. Kaplinskiy, and R. N. Kitsis, “Cell death in the pathogenesis of heart disease: mechanisms and significance,” Annual Review of Physiology, vol. 72, no. 1, pp. 19–44, 2010.
[4] C. J. Rhodes, “Type 2 diabetes-a matter of beta-cell life and death?,” Science, vol. 307, no. 5708, pp. 380–384, 2005.
[5] S. P. Davies, S. A. Hawley, A. Woods, D. Carling, T. A. Haysstead, and D. G. Hardie, “Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure,” European Journal of Biochemistry, vol. 223, no. 2, pp. 351–357, 1994.
[6] D. G. Hardie and S. A. Hawley, “AMP-activated protein kinase: the energy charge hypothesis revisited,” BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology, vol. 23, no. 12, pp. 1112–1119, 2001.
[7] P. C. Cheung, I. P. Salt, S. P. Davies, D. G. Hardie, and D. Carling, “Characterization of AMP-activated protein kinase γ-subunit isoforms and their role in AMP binding,” Biochemical Journal, vol. 346, no. 3, pp. 659–669, 2000.
[8] R. R. Russell 3rd, J. Li, D. L. Coven et al., “AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury,” The Journal of Clinical Investigation, vol. 114, no. 4, pp. 495–503, 2004.
[9] J. Li, D. L. Coven, E. J. Miller et al., “Activation of AMPK α- and γ-isofoms in the intact ischemic rat heart,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 291, no. 4, pp. H1927–H1934, 2006.
[10] G. Polekhina, A. Gupta, B. J. Michell et al., “AMPK β Subunit Targets Metabolic Stress Sensing to Glycogen,” Current Biology, vol. 13, no. 10, pp. 867–871, 2003.
[11] J. W. Scott, S. A. Hawley, K. A. Green et al., “CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations,” The Journal of Clinical Investigation, vol. 113, no. 2, pp. 274–284, 2004.
[12] D. Carling, F. V. Mayer, M. J. Sanders, and S. J. Gamblin, “AMP-activated protein kinase: nature’s energy sensor,” Nature Chemical Biology, vol. 7, no. 8, pp. 512–518, 2011.
[13] M. J. Sanders, P. O. Grondin, B. D. Hegarty, M. A. Snowden, and D. Carling, “Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade,” The Biochemical Journal, vol. 403, no. 1, pp. 139–148, 2007.

Data Availability
Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.

Ethical Approval
The manuscript is prepared by following the ethical guidelines of the Journal.

Conflicts of Interest
The authors declare no conflict of interest in this work.
Oxidative Medicine and Cellular Longevity

[14] B. Xiao, M. J. Sanders, E. Underwood et al., “Structure of mammalian AMPK and its regulation by ADP,” Nature, vol. 472, no. 7342, pp. 230–233, 2011.

[15] F. A. Ross, T. E. Jensen, and D. G. Hardie, “Differential regulation by AMP and ADP of AMPK complexes containing different γ subunit isoforms,” The Biochemical Journal, vol. 473, no. 2, pp. 189–199, 2016.

[16] S. P. Davies, N. R. Helps, P. T. Cohen, and D. G. Hardie, “AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2Cα and native bovine protein phosphatase-2Aγ,” FEBS Letters, vol. 377, no. 3, pp. 421–425, 1995.

[17] J. S. Oakhill, R. Steel, Z. P. Chen et al., “AMPK is a direct adenylate charge-regulated protein kinase,” Science (New York, N.Y.), vol. 332, no. 6036, pp. 1433–1435, 2011.

[18] B. Xiao, R. Heath, P. Saito et al., “Structural basis for AMP binding to mammalian AMP-activated protein kinase,” Nature, vol. 449, no. 7161, pp. 496–500, 2007.

[19] S. Ignoul and J. Eggermont, “CBS domains: structure, function, and pathology in human proteins,” American Journal of Physiology - Cellular Physiology, vol. 289, no. 6, pp. C1369–C1378, 2005.

[20] R. Viana, M. C. Towler, D. A. Pan et al., “A Conserved Sequence Immediately N-terminal to the Bateman Domains in AMP-activated Protein Kinase γ Subunits Is Required for the Interaction with the β Subunits,” The Journal of Biological Chemistry, vol. 282, no. 22, pp. 16117–16125, 2007.

[21] B. E. Kemp, J. S. Oakhill, and J. W. Scott, “AMPK structure and regulation from three angles,” Structure, vol. 15, no. 10, pp. 1161–1163, 2007.

[22] S. A. Hawley, J. Boudeau, J. L. Reid et al., “Complexes between the LKB1 tumor suppressor, STRADA/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade,” Journal of Biology, vol. 2, no. 4, p. 28, 2003.

[23] A. Woods, K. Dickerson, R. Heath et al., “Ca2+/calmodulin-dependent protein kinase β-acts upstream of AMP-activated protein kinase in mammalian cells,” Cell Metabolism, vol. 2, no. 1, pp. 21–33, 2005.

[24] D. R. Alessi, K. Sakamoto, and J. R. Bayascas, “LKB1-dependent signaling pathways,” Annual Review of Biochemistry, vol. 75, no. 1, pp. 137–163, 2006.

[25] K. Sakamoto, O. Göransson, D. G. Hardie, and D. R. Alessi, “Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR,” American Journal of Physiology Endocrinology and Metabolism, vol. 287, no. 2, pp. E310–E317, 2004.

[26] K. Sakamoto, E. Zarrinpashneh, G. R. Budas et al., “Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKα2 but not AMPKα1,” American Journal of Physiology Endocrinology and Metabolism, vol. 290, no. 5, pp. E780–E788, 2006.

[27] K. Sakamoto, A. McCarthy, D. Smith et al., “Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction,” The EMBO Journal, vol. 24, no. 10, pp. 1810–1820, 2005.

[28] R. J. Shaw, K. A. Lamia, D. Vasquez et al., “The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin,” Science (New York, N.Y.), vol. 310, no. 5754, pp. 1642–1646, 2005.

[29] H. J. Koh, D. E. Arnold, N. Fuji et al., “Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3,” Molecular and Cellular Biology, vol. 26, no. 22, pp. 8217–8227, 2006.

[30] S. P. Hong, M. Momcilovic, and M. Carlson, “Function of Mammalian LKB1 and Ca2+/calmodulin-dependent Protein Kinase α as Snf1-activating Kinases in Yeast,” The Journal of Biological Chemistry, vol. 280, no. 23, pp. 21804–21809, 2005.

[31] P. T. Mungai, G. B. Waypa, A. Jairaman et al., “Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels,” Molecular and Cellular Biology, vol. 31, no. 17, pp. 3531–3545, 2011.

[32] S. Salle-Lefort, S. Miard, M. A. Nolin et al., “Hypoxia upregulates Malat1 expression through a CaMKK/AMPK/HIF-1α axis,” International Journal of Oncology, vol. 49, no. 4, pp. 1731–1736, 2016.

[33] G. Ghislat, M. Patron, R. Rizzuto, and E. Knecht, “Withdrawal of Essential Amino Acids Increases Autophagy by a Pathway Involving Ca2+/calmodulin-dependent Kinase β (CaMKK-β),” The Journal of Biological Chemistry, vol. 287, no. 46, pp. 38625–38636, 2012.

[34] S. Fogarty, S. A. Hawley, K. A. Green, N. Saner, K. J. Mustard, and D. G. Hardie, “Calmodulin-dependent protein kinase kinase-β activates AMPK without forming a stable complex: synergistic effects of Ca2+ and AMP,” The Biochemical Journal, vol. 426, no. 1, pp. 109–118, 2010.

[35] C. A. Witzak, N. Fujii, M. F. Hirshman, and L. J. Goodyear, “Ca2+/calmodulin-Dependent Protein Kinase α-Regulates Skeletal Muscle Glucose Uptake Independent of AMP-Activated Protein Kinase and Akt Activation,” Diabetes, vol. 56, no. 5, pp. 1403–1409, 2007.

[36] M. Momcilovic, S. P. Hong, and M. Carlson, “Mammalian TAK1 Activates Snf1 Protein Kinase in Yeast and Phosphorylates AMP-activated Protein Kinase in Vivo,” The Journal of Biological Chemistry, vol. 281, no. 35, pp. 25336–25343, 2006.

[37] M. Xie, D. Zhang, J. R. B. Dyck et al., “A pivotal role for endogenous TGF-β-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17378–17383, 2006.

[38] N. Djourou, R. D. Tuerk, M. Suter et al., “PKA phosphorylates and inactivates AMPKα1 to promote efficient lipolysis,” The EMBO Journal, vol. 29, no. 2, pp. 469–481, 2010.

[39] T. Pulinilkunnil, H. He, D. Kong et al., “Adrenergic Regulation of AMP-activated Protein Kinase in Brown Adipose Tissue in Vivo,” The Journal of Biological Chemistry, vol. 281, no. 11, pp. 8798–8809, 2011.

[40] S. Kovacic, C. L. M. Soltys, A. J. Barr, I. Shiojima, K. Walsh, and J. R. B. Dyck, “Akt Activity Negatively Regulates Phosphorylation of AMP-activated Protein Kinase in the Heart,” The Journal of Biological Chemistry, vol. 278, no. 41, pp. 39422–39427, 2003.

[41] M. Y. Wang and R. H. Unger, “Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone,” American Journal of Physiology Endocrinology and Metabolism, vol. 288, no. 1, pp. E216–E221, 2005.

[42] Y. Wu, P. Song, J. Xu, M. Zhang, and M. H. Zou, “Activation of Protein Phosphatase 2A by Palmitate Inhibits AMP-activated Protein Kinase,” The Journal of Biological Chemistry, vol. 282, no. 13, pp. 9777–9788, 2007.
Biology of Lipids mediated long-chain fatty acid uptake into cardiomyocytes, 
“Causal role for LKB1 to AMPK signaling abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle,” American Journal of Physiology-Endocrinology and Metabolism, vol. 297, no. 3, pp. E665–E675, 2009.

X. Xi, J. Han, and J. Z. Zhang, “Stimulation of Glucose Transport by AMP-activated Protein Kinase via Activation of p38 Mitogen-activated Protein Kinase,” Journal of Biological Chemistry, vol. 276, no. 44, pp. 41029–41034, 2001.

A. S. Marsin, L. Bertrand, M. H. Rider et al., “Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia,” Current Biology, vol. 10, no. 20, pp. 1247–1255, 2000.

S. B. Jørgensen, J. N. Nielsen, J. B. Birk et al., “The α2–5’ AMP-activated protein kinase is a site 2 glycoen synthase kinase in skeletal muscle and is responsive to glucose loading.” Diabetes, vol. 53, no. 12, pp. 3074–3081, 2004.

S. H. Koo, L. Flechner, L. Qi et al., “The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism,” Nature, vol. 437, no. 7062, pp. 1109–1114, 2005.

M. M. Mihaylova, D. S. Vasquez, K. Ravnskjaer et al., “Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis,” Cell, vol. 145, no. 4, pp. 607–621, 2011.

D. D. J. Habets, W. A. Coumans, M. el Hasnaoui et al., “Crucial role for LKB1 to AMPKα2 axis in the regulation of CD36-mediated long-chain fatty acid uptake into cardiomyocytes,” Biochimica et Biophysica Acta (BBA) - Molecular and Cellular Biology of Lipids, vol. 1791, no. 3, pp. 212–219, 2009.

G. F. Merrill, E. J. Kurth, D. G. Hardie, and W. W. Winder, “AICAR ribosides increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle,” The American Journal of Physiology, vol. 273, no. 6, pp. E1107–E1112, 1997.

S. P. Davies, D. Carling, M. R. Munday, and D. G. Hardie, “Diurnal rhythm of phosphorylation of rat liver acetyl-CoA carboxylase by the AMP-activated protein kinase, demonstrated using freeze-clamping. Effects of high fat diets,” European Journal of Biochemistry, vol. 203, no. 3, pp. 615–623, 1992.

Y. Li, S. Xu, M. Mihaylova et al., “AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice,” Cell Metabolism, vol. 13, no. 4, pp. 376–388, 2011.

D. M. Muoio, K. Seefeld, L. A. Witters, and R. A. Coleman, “AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target,” The Biochemical Journal, vol. 338, no. 3, pp. 783–791, 1999.

P. R. Clarke and D. G. Hardie, “Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver,” The EMBO Journal, vol. 9, no. 8, pp. 2439–2446, 1990.

S. Hoppe, H. Bierhoff, I. Cado et al., “AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 42, pp. 17781–17786, 2009.

K. Inoki, T. Zhu, and K. L. Guan, “TSC2 mediates cellular energy response to control cell growth and survival,” Cell, vol. 115, no. 5, pp. 577–590, 2003.

S. Jäger, C. Handschin, J. St.-Pierre, and B. M. Spiegelman, “AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 12017–12022, 2007.

C. Cantó, L. Q. Jiang, A. S. Deshmukh et al., “Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle,” Cell Metabolism, vol. 11, no. 3, pp. 213–219, 2010.

Z. Yang and D. J. Klionsky, “Eaten alive: a history of macroautophagy,” Nature Cell Biology, vol. 12, no. 9, pp. 814–822, 2010.

A. Nakai, O. Yamaguchi, T. Takeda et al., “The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress,” Nature Medicine, vol. 13, no. 5, pp. 619–624, 2007.

I. Nishino, J. Fu, K. Tanji et al., “Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease),” Nature, vol. 406, no. 6798, pp. 906–910, 2000.

Y. Tanaka, G. Guhde, A. Suter et al., “Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice,” Nature, vol. 406, no. 6798, pp. 902–906, 2000.

M. N. Corradetti and K. L. Guan, “Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?,” Oncogene, vol. 25, no. 48, pp. 6347–6360, 2006.

A. J. Meijer and P. Codogno, “Signalling and autophagy regulation in health, aging and disease,” Molecular Aspects of Medicine, vol. 27, no. 5–6, pp. 411–425, 2006.

R. J. Shaw, “LKB1 and AMP-activated protein kinase control of mTOR signalling and growth,” Acta Physiologica (Oxford, England), vol. 196, no. 1, pp. 65–80, 2009.

C. He, H. Zhu, H. Li, M. H. Zou, and Z. Xie, “Dissociation of Bcl-2-Bclin1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes,” Diabetes, vol. 62, no. 4, pp. 1270–1281, 2013.

C. Mammucari, G. Milan, V. Romanello et al., “FoxO3 controls autophagy in skeletal muscle in vivo,” Cell Metabolism, vol. 6, no. 6, pp. 458–471, 2007.

A. Sengupta, J. D. Molkentin, and K. E. Yutzey, “FoxO Transcription Factors Promote Autophagy in Cardiomyocytes,” The Journal of Biological Chemistry, vol. 284, no. 41, pp. 28319–28331, 2009.

D. F. Egan, D. B. Shackelford, M. M. Mihaylova et al., “Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy,” Science, vol. 331, no. 6016, pp. 456–461, 2011.

J. Kim, M. Kundu, B. Viollet, and K. L. Guan, “AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1,” Nature Cell Biology, vol. 13, no. 2, pp. 132–141, 2011.

M. N. Corradetti, K. Inoki, N. Bardeesy, R. A. DePinho, and K. L. Guan, “Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex
and Peutz-Jeghers syndrome,” *Genes & Development*, vol. 18, no. 13, pp. 1533–1538, 2004.

[74] M. Høyer-Hansen, L. Bastholm, P. Szyriarowski et al., “Control of Macroautophagy by Calcium, Calmodulin-Dependent Kinase-β, and Bcl-2,” *Molecular Cell*, vol. 25, no. 2, pp. 193–205, 2007.

[75] H. R. Samari and P. O. Seglen, “Inhibition of Hepatocytic Autophagy by Adenosine, Aminomidozale-4-carboxamide Riboside, and N²-Mercaptopurine Riboside: Evidence for involvement of amp-activated protein kinase,” *The Journal of Biological Chemistry*, vol. 273, no. 37, pp. 23758–23763, 1998.

[76] B. S. Jhun, Q. Jin, Y. T. Oh et al., “5-Aminomidozale-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-α production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages,” *Biochemical and Biophysical Research Communications*, vol. 318, no. 2, pp. 372–380, 2004.

[77] D. Meley, C. Baury, J. H. P. M. Houben-Weerts et al., “AMP-activated Protein Kinase and the Regulation of Autophagic Proteolysis,” *The Journal of Biological Chemistry*, vol. 281, no. 46, pp. 34870–34879, 2006.

[78] H. D. Sybers, J. Ingwall, and M. DeLuca, “Autophagy in cardiac myocytes,” *Recent Advances in Studies on Cardiac Structure and Metabolism*, vol. 12, pp. 453–463, 1976.

[79] H. Shimomura, F. Terasaki, T. Hayashi, Y. Kitaura, T. Isomura, and H. Suma, “Autophagic degeneration as a possible mechanism of myocardial cell death in dilated cardiomyopathy,” *Japanese Circulation Journal*, vol. 65, no. 11, pp. 965–968, 2001.

[80] A. Elsässer, A. M. Vogt, H. Nef et al., “Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death,” *Journal of the American College of Cardiology*, vol. 43, no. 12, pp. 2191–2199, 2004.

[81] L. Yan, D. E. Vatner, S. J. Kim et al., “Autophagy in chronically ischemic myocardium,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 39, pp. 13807–13812, 2005.

[82] L. Yan, J. Sadoshima, D. E. Vatner, and S. F. Vatner, “Autophagy: a novel protective mechanism in chronic ischemia,” *Cell Cycle*, vol. 5, no. 11, pp. 1175–1177, 2006.

[83] Y. Matsui, H. Takagi, X. Qu et al., “Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy,” *Circulation Research*, vol. 100, no. 6, pp. 914–922, 2007.

[84] A. Hamacher-Brady, N. R. Brady, S. E. Logue et al., “Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy,” *Cell Death and Differentiation*, vol. 14, no. 1, pp. 146–157, 2007.

[85] L. Valentim, K. M. Laurence, P. A. Townsend et al., “Uroca- tin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury,” *Journal of Molecular and Cellular Cardiology*, vol. 40, no. 6, pp. 846–852, 2006.

[86] Z. V. Wang, B. A. Rothermel, and J. A. Hill, “Autophagy in Hypertensive Heart Disease,” *The Journal of Biological Chemistry*, vol. 285, no. 12, pp. 8509–8514, 2010.

[87] V. W. Dolinsky and J. R. B. Dyck, “Role of AMP-activated protein kinase in healthy and diseased hearts,” *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 291, no. 6, pp. H2557–H2569, 2006.

[88] H. Takagi, Y. Matsu, S. Hirono, H. Sakoda, T. Asano, and J. Sadoshima, “AMPK mediates autophagy during myocardial ischemia in vivo,” *Autophagy*, vol. 3, no. 4, pp. 405–407, 2007.

[89] R. Scherz-Shouval, E. Shvets, E. Fass, H. Shorer, L. Gil, and Z. Elazar, “Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4,” *The EMBO Journal*, vol. 26, no. 7, pp. 1749–1760, 2007.

[90] C. C. Glembotski, “Endoplasmic reticulum stress in the heart,” *Circulation Research*, vol. 101, no. 10, pp. 975–984, 2007.

[91] M. Chen, D. J. Won, S. Krajewski, and R. A. Gottlieb, “Cardi- pain and Mitochondria in Ischemia/Reperfusion Injury,” *The Journal of Biological Chemistry*, vol. 277, no. 32, pp. 29181–29186, 2002.

[92] J. Shao, C. Miao, Z. Geng, M. Gu, Y. Wu, and Q. Li, “Effect of eNOS on ischemic postconditioning-induced autophagy against ischemia/reperfusion injury in mice,” *BiomediResearch International*, vol. 2019, Article ID 5201014, 11 pages, 2019.

[93] B. A. Rothermel and J. A. Hill, “Myocyte autophagy in heart disease: friend or foe?” *Autophagy*, vol. 3, no. 6, pp. 632–634, 2007.

[94] S. D. Mayanskaia, N. N. Mayanskaia, A. V. Efremov, and G. S. Yakobson, “Activity of lysosomal apparatus in rat myocardium during experimental coronary and noncoronary myocardial damage,” *Bulletin of Experimental Biology and Medicine*, vol. 129, no. 6, pp. 530–532, 2000.

[95] S. Pattingre, A. Tassa, X. Qu et al., “Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy,” *Cell*, vol. 122, no. 6, pp. 927–939, 2005.

[96] J. Grünfenfelder, D. N. Miniati, S. Murata et al., “Upregulation of Bcl-2 through caspase-3 inhibition ameliorates ischemia/reperfusion injury in rat cardiac allografts,” *Circulation*, vol. 104, Supplement 1, pp. I-202–I-206, 2001.

[97] S. Yousefi, R. Perozzo, I. Schmid et al., “Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis,” *Nature Cell Biology*, vol. 8, no. 10, pp. 1124–1132, 2006.

[98] K. M. Mellor, J. R. Bell, M. J. Young, R. H. Ritchie, and L. M. D. Delbridge, “Myocardial autophagy activation and suppressed survival signaling is associated with insulin resistance in fructose-fed mice,” *Journal of Molecular and Cellular Cardiology*, vol. 50, no. 6, pp. 1035–1043, 2011.

[99] W. C. Stanley, G. D. Lopaschuk, and J. G. McCormack, “Regulation of energy substrate metabolism in the diabetic heart,” *Cardiovascular Research*, vol. 34, no. 1, pp. 25–33, 1997.

[100] D. J. Hausenloy and D. M. Yellon, “New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway,” *Cardiovascular Research*, vol. 61, no. 3, pp. 448–460, 2004.

[101] Z. Xie, K. Lau, B. Eby et al., “Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice,” *Diabetes*, vol. 60, no. 6, pp. 1770–1778, 2011.

[102] Z. Xie, C. He, and M. H. Zou, “AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy,” *Autophagy*, vol. 7, no. 10, pp. 1254–1255, 2011.

[103] X. Xu, S. Kobayashi, K. Chen et al., “Diminished Autophagy Limits Cardiac Injury in Mouse Models of Type 1 Diabetes,” *The Journal of Biological Chemistry*, vol. 288, no. 25, pp. 18077–18092, 2013.
L. Cai and Y. J. Kang, M. H. Zou and Z. Xie, "Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death," Diabetes, vol. 50, no. 6, pp. 1414–1424, 2001.

A. Frustaci, J. Kajstura, C. Chimenti et al., "Oxidative Medicine and Cellular Longevity No. 12, pp. 1123–1130, 2002.

Y. Li, Z. H. Zhou, M. H. Chen et al., "AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes," American Journal of Physiology-Heart and Circulatory Physiology, vol. 307, no. 8, pp. H1120–H1133, 2014.

D. Vercaemen, R. Beyaert, G. Denecker et al., "Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor," The Journal of Experimental Medicine, vol. 187, no. 9, pp. 1477–1485, 1998.

P. Vandenabeele, L. Galluzzi, T. vanden Berghe, and G. Kroemer, "Molecular mechanisms of necroptosis: an ordered cellular explosion," Nature Reviews Molecular Cell Biology, vol. 11, no. 10, pp. 700–714, 2010.

E. Rieser, S. M. Cordier, and H. Walczak, "Linear ubiquitination: a newly discovered regulator of cell signalling," Trends in Biochemical Sciences, vol. 38, no. 2, pp. 94–102, 2013.

H. Walczak, "TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer," Immunological Reviews, vol. 244, no. 1, pp. 9–28, 2011.

N. Vanlangenakker, T. vanden Berghe, P. Bogaert et al., "cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production," Cell Death and Differentiation, vol. 18, no. 4, pp. 656–665, 2011.

M. Muzio, B. R. Stockwell, H. R. Stennicke, G. S. Salvesen, and V. M. Dixit, "An Induced Proximity Model for Caspase-8 Activation," The Journal of Biological Chemistry, vol. 273, no. 5, pp. 2926–2930, 1998.

N. Vanlangenakker, T. vanden Berghe, and P. Vandenabeele, "Many stimuli pull the necrotic trigger, an overview," Cell Death and Differentiation, vol. 19, no. 1, pp. 75–86, 2012.

W. J. Kaiser, J. W. Upton, A. B. Long et al., "RIP3 mediates the embryonic lethality of caspase-8-deficient mice," Nature, vol. 471, no. 7338, pp. 368–372, 2011.

A. Oberst, C. P. Dillon, R. Weinlich et al., "Catalytic activity of the caspase-8-FLIP L complex inhibits RIPK3-dependent necrosis," Nature, vol. 471, no. 7338, pp. 363–367, 2011.

S. B. Berger, V. Kasparcova, S. Hoffman et al., "Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice," Journal of Immunology (Baltimore, Md. : 1950), vol. 192, no. 12, pp. 5476–5480, 2014.

K. Newton, D. L. Dugger, K. E. Wickliffe et al., "Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis," Science, vol. 343, no. 6177, pp. 1357–1360, 2014.

J. Li, T. McQuade, A. B. Siemer et al., "The RIP1/RIP3 necroosome forms a functional amyloid signaling complex required for programmed necrosis," Cell, vol. 150, no. 2, pp. 339–350, 2012.

J. Zhao, S. Jitkaew, Z. Cai et al., "Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 14, pp. 5322–5327, 2012.

L. Sun, H. Wang, Z. Wang et al., "Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase," Cell, vol. 148, no. 1-2, pp. 213–227, 2012.

D. E. Christoferson and J. Yuan, "Necroptosis as an alternative form of programmed cell death," Current Opinion in Cell Biology, vol. 22, no. 2, pp. 263–268, 2010.
[166] N. Festjens, T. vanden Berghe, S. Cornelis, and P. Vandenabeele, "RIP1, a kinase on the crossroads of a cell’s decision to live or die," *Cell Death and Differentiation*, vol. 14, no. 3, pp. 400–410, 2007.

[167] M. I. Oerlemans, J. Liu, F. Arslan et al., "Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo," *Basic Research in Cardiology*, vol. 107, no. 4, pp. 270, 2012.

[168] Y. V. Dmitriev, S. M. Minasian, E. A. Demchenko, and M. M. Galagudza, "Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia–reperfusion," *Bulletin of Experimental Biology and Medicine*, vol. 155, no. 2, pp. 245–248, 2013.

[169] S. Koshinuma, M. Miyamae, K. Kaneda, J. Kotani, and V. M. Figueredo, "Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury," *Nature Chemical Biology*, vol. 1, no. 2, pp. 112–119, 2005.

[170] S. Y. Lim, S. M. Davidson, M. M. Mocanu, D. M. Yellon, and C. C. T. Smith, "The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore," *Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy*, vol. 21, no. 4, pp. 227–233, 2007.

[171] A. Degterev, Z. Huang, M. Boyce et al., "Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury," *Nature Chemical Biology*, vol. 1, no. 2, pp. 112–119, 2005.

[172] L. Sun, M. Zhao, X. J. Yu et al., "Necrostatin: a potentially novel cardioprotective agent?", *Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy*, vol. 21, no. 6, pp. 467–469, 2007.

[173] M. Luedde, M. Lutz, N. Carter et al., "RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction," *Cardiovascular Research*, vol. 103, no. 2, pp. 206–216, 2014.

[174] A. Linkermann, J. H. Bräsen, M. Darding et al., "Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 29, pp. 12024–12029, 2013.

[175] Y. S. Wang, P. Yu, Y. Wang et al., "AMP-activated protein kinase protects against necroptosis via regulation of Keap1-PGAM5 complex," *International Journal of Cardiology*, vol. 259, pp. 153–162, 2018.

[176] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht et al., "Ferroptosis: an iron-dependent form of nonapoptotic cell death," *Cell*, vol. 149, no. 5, pp. 1060–1072, 2012.

[177] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir et al., "Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease," *Cell*, vol. 171, no. 2, pp. 273–285, 2017.

[178] X. Chen, J. Li, R. Kang, D. J. Klionsky, and D. Tang, "Ferroptosis: machinery and regulation," *Autophagy*, vol. 17, no. 9, pp. 2054–2081, 2021.

[179] D. Tang, X. Chen, R. Kang, and G. Kroemer, "Ferroptosis: molecular mechanisms and health implications," *Cell Research*, vol. 31, no. 2, pp. 107–125, 2021.

[180] M. Gao, P. Monian, N. Quadri, R. Ramasamy, and X. Jiang, "Glutaminolysis and transferrin regulate ferroptosis," *Molecular Cell*, vol. 59, no. 2, pp. 298–308, 2015.

[181] W. Li, G. Feng, J. M. Gauthier et al., "Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation," *The Journal of Clinical Investigation*, vol. 129, no. 6, pp. 2293–2304, 2019.

[182] Y. Feng, N. B. Madungwe, A. D. Imam Aliagan, N. Tombo, and J. C. Bopassa, "Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels," *Biochemical and Biophysical Research Communications*, vol. 520, no. 3, pp. 606–611, 2019.

[183] H. Bulluck, S. Rosmini, A. Abdel-Gadir et al., "Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling," *Circulation: Cardiovascular Imaging*, vol. 9, no. 10, article e004940, 2016.

[184] Y. Baba, J. K. Higa, B. K. Shimada et al., "Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes,", *American Journal of Physiology Heart and Circulatory Physiology*, vol. 314, no. 3, pp. H659–H668, 2018.

[185] E. R. Dabkowski, C. L. Williamson, and J. M. Hollander, "Mitochondria-specific transgenic overexpression of phospholipid hydroperoxide glutathione peroxidase (GPx4) attenuates ischemia/reperfusion-associated cardiac dysfunction,", *Free Radical Biology & Medicine*, vol. 45, no. 6, pp. 855–865, 2008.

[186] X. Fang, H. Wang, D. Han et al., "Ferroptosis as a target for protection against cardiomyopathy,", *Proceedings of the National Academy of Sciences of the United States of America*, vol. 116, no. 7, pp. 2672–2680, 2019.

[187] P. Guan and N. Wang, "Mammalian target of rapamycin coordinates iron metabolism with iron-sulfur cluster assembly enzyme and tristetraprolin,", *Nutrition*, vol. 30, no. 9, pp. 968–974, 2014.

[188] M. Bayeva, A. Khachaduri, S. Puig et al., "mTOR regulates cellular iron homeostasis through tristetraprolin,", *Cell Metabolism*, vol. 16, no. 5, pp. 645–657, 2012.

[189] C. Gorrini, I. S. Harris, and T. W. Mak, "Modulation of oxidative stress as an anticancer strategy,", *Nature Reviews Drug Discovery*, vol. 12, no. 12, pp. 931–947, 2013.

[190] Y. Baba, J. K. Higa, B. K. Shimada et al., "Ferroptosis: a potentially novel cardioprotective agent,", *Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy*, vol. 21, no. 6, pp. 467–469, 2007.

[191] T. N. Donnelly, R. Castro-Portuguez, and D. D. Zhang, "Ferroptosis:
[192] R. Zhang, "Ferroptosis: a novel mechanism via mitochondrial biogenesis and function involving the PGC-1α pathway,", *Journal of Cellular Physiology*, vol. 228, no. 6, pp. 1238–1248, 2013.

[193] H. L. Lee, F. Zandkarimi, Y. Zhang et al., "Energy-stress-mediated AMPK activation inhibits ferroptosis,", *Nature Cell Biology*, vol. 22, no. 2, pp. 225–234, 2020.

[194] Q. Liu, J. C. Docherty, J. C. T. Rendell, A. S. Clanachan, and G. D. Lopashuk, "High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation,", *Journal of the American College of Cardiology*, vol. 39, no. 4, pp. 718–725, 2002.

[195] D. Shao, S. I. Oka, T. Liu et al., "A redox-dependent mechanism for regulation of AMPK activation by thioredoxin1 during energy starvation,", *Cell Metabolism*, vol. 19, no. 2, pp. 232–245, 2014.

[196] L. Sun, M. Zhao, X. J. Yu et al., "Cardioprotection by acetylcholine: a novel mechanism via mitochondrial biogenesis and function involving the PGC-1α pathway,", *Journal of Cellular Physiology*, vol. 228, no. 6, pp. 1238–1248, 2013.

[197] L. M. Yu, X. Dong, X. D. Xue et al., "Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to
ischemia-reperfusion injury by improving mitochondrial quality control: role of SIRT6,” *Journal of Pineal Research*, vol. 70, no. 1, article e12698, 2021.

[196] C. C. Thornton, F. al-Rashed, D. Calay et al., “Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation,” *Annals of the Rheumatic Diseases*, vol. 75, no. 2, pp. 439–448, 2016.

[197] D. A. Butterfield and B. Halliwell, “Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease,” *Nature Reviews Neuroscience*, vol. 20, no. 3, pp. 148–160, 2019.

[198] G. Davi, A. Falco, and C. Patrono, “Lipid peroxidation in diabetes mellitus,” *Antioxidants & Redox Signaling*, vol. 7, no. 1-2, pp. 256–268, 2005.

[199] X. Song, J. Liu, F. Kuang et al., “PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis,” *Cell Reports*, vol. 34, no. 8, article 108767, 2021.

[200] N. Li, W. Jiang, W. Wang, R. Xiong, X. Wu, and Q. Geng, “Ferroptosis and its emerging roles in cardiovascular diseases,” *Pharmacological Research*, vol. 166, article 105466, 2021.

[201] J. Y. Duan, X. Lin, F. Xu et al., “Ferroptosis and its potential role in metabolic diseases: a curse or revitalization?,” *Frontiers in Cell and Development Biology*, vol. 9, article 701788, 2021.

[202] X. Wu, Y. Li, S. Zhang, and X. Zhou, “Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress,” *DNA and Cell Biology*, vol. 39, no. 2, pp. 210–225, 2020.

[203] W. Li, W. Li, Y. Leng, Y. Xiong, and Z. Xia, “Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress,” *DNA and Cell Biology*, vol. 39, no. 2, pp. 210–225, 2020.

[204] S. H. Dai, T. Chen, X. Li et al., “Sirt3 confers protection against neuronal ischemia by inducing autophagy: involvement of the AMPK-mTOR pathway,” *Free Radical Biology & Medicine*, vol. 108, pp. 345–353, 2017.

[205] M. Gao, P. Monian, Q. Pan, W. Zhang, J. Xiang, and X. Jiang, “Ferroptosis is an autophagic cell death process,” *Cell Research*, vol. 26, no. 9, pp. 1021–1032, 2016.

[206] Z. Wu, Y. Geng, X. Lu et al., “Chaperone-mediated autophagy is involved in the execution of ferroptosis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 116, no. 8, pp. 2996–3005, 2019.

[207] D. Tang, R. Kang, T. V. Berge, P. Vandenabeele, and G. Kroemer, “The molecular machinery of regulated cell death,” *Cell Research*, vol. 29, no. 5, pp. 347–364, 2019.

[208] D. Han, L. Jiang, X. Gu et al., “SIRT3 deficiency is resistant to autophagy-dependent ferroptosis by inhibiting the AMPK/mTOR pathway and promoting GPX4 levels,” *Journal of Cellular Physiology*, vol. 235, no. 11, pp. 8839–8851, 2020.

[209] X. Song, S. Zhu, P. Chen et al., “AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System X-β Activity,” *Current Biology*, vol. 28, no. 15, pp. 2388–2399.e5, 2018.

[210] H. Zang, W. Wu, L. Qi et al., “Autophagy inhibition enables Nrf2 to exaggerate the progression of diabetic cardiomyopathy in mice,” *Diabetes*, vol. 69, no. 12, pp. 2720–2734, 2020.

[211] S. H. Choi, Y. W. Kim, and S. G. Kim, “AMPK-mediated GSK3β inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress,” *Biochemical Pharmacology*, vol. 79, no. 9, pp. 1352–1362, 2010.

[212] M. Salazar, A. I. Rojo, D. Velasco, R. M. de Sagarra, and A. Cuadrado, “Glycogen Synthase Kinase-3β Inhibits the Xenobiotic and Antioxidant Cell Response by Direct Phosphorylation and Nuclear Exclusion of the Transcription Factor Nrf2,” *The Journal of Biological Chemistry*, vol. 281, no. 21, pp. 14841–14851, 2006.

[213] Y. Sun, S. Zhou, H. Guo et al., “Protective effects of sulforaphane on type 2 diabetes-induced cardiomyopathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 function,” *Metabolism, Clinical and Experimental*, vol. 102, article 154002, 2020.

[214] F. Rizvi, S. Shukla, and P. Kakkar, “Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt/GSK3β/Fyn kinase axis during oxidative hepatocellular toxicity,” *Cell Death & Disease*, vol. 5, no. 3, article e1153, 2014.

[215] X. Wang, X. Chen, W. Zhou et al., “Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways,” *Acta Pharmaceutica Sinica B*, vol. 12, no. 2, pp. 708–722, 2022.

[216] J. Gu, Y. Cheng, H. Wu et al., “Metallothionein is downstream of Nrf2 and partially mediates sulforaphane prevention of diabetic cardiomyopathy,” *Diabetes*, vol. 66, no. 2, pp. 529–542, 2017.

[217] D. G. Hardie, “Neither LKB1 nor AMPK are the direct targets of metformin,” *Gastroenterology*, vol. 131, no. 3, pp. 973–975, 2006.

[218] L. G. Fryer, A. Parbu-Patel, and D. Carling, “The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways,” *The Journal of Biological Chemistry*, vol. 277, no. 28, pp. 25226–25232, 2002.

[219] J. T. Chin, J. J. Troke, N. Kimura et al., “A novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection,” *The Yale Journal of Biology and Medicine*, vol. 84, no. 4, pp. 423–432, 2011.

[220] A. Morrison and J. Li, “PPAR-γ and AMPK - Advantageous targets for myocardial ischemia/reperfusion therapy,” *Biochemical Pharmacology*, vol. 82, no. 3, pp. 195–200, 2011.

[221] A. Morrison, X. Yan, C. Tong, and J. Li, “Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in non-diabetic mice,” *American Journal of Physiology Heart and Circulatory Physiology*, vol. 301, no. 3, pp. H895–H902, 2011.

[222] J. R. Dyck and G. D. Lopaschuk, “AMPK alterations in cardiac physiology and pathology: enemy or ally?,” *The Journal of Physiology*, vol. 574, no. 1, pp. 95–112, 2006.